Explore more price target data and ratings for Altimmune, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Altimmune, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is…
Shares of Altimmune (ALT) rose as much as 10% in late morning trading on Tuesday before paring gains after the company reported positive early results from a mid-stage study of its experimental drug pemvidutide in people with alcohol use disorder.ALT stock was trading 4% lower at the time of writin…
Pemvidutide demonstrated robust efficacy in reducing heavy drinking days and improving key secondary endpoints in moderate to severe AUD patients, with favorable safety and significant benefits on liver and metabolic measures. Both FDA and EMA registrational endpoints were met, supporting advanceme…
Shares of Altimmune (ALT) jumped more than 10% in pre-market trading on Tuesday, after it reported positive topline results for its therapy to treat patients with moderate to severe alcohol use disorder (AUD), a condition with significant unmet medical need and limited treatment options.If the pre…
Altimmune announced positive topline Phase 2 results for pemvidutide 2.4 mg showing a significant reduction in heavy drinking days versus placebo.Key Highlights:Original SEC Filing: Altimmune, Inc. [ ALT ] - 8-K - Jul. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Consider ver…
